Atlas Trials

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Clinical trial NCT03383978 · RECRUITING

Trial details

NCT number
NCT03383978
Sponsor
Johann Wolfgang Goethe University Hospital
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Glioblastoma
Start date
2017-12-01
Primary completion
2027-12-31
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.